All posts
-
Advisors recommend Novo Nordisk to leave Russia
Although Novo Nordisk’s sales in Russia are made with humanitarianism in mind, organization indirectly adds tax obligation earnings that money the battle in Ukraine, state ex…
-
Novo Nordisk on Lilly’s new weight loss study: “We have yet to see complete data”
Wednesday’s comparative research, the primary of its type, confirmed that Eli Lilly’s tirzepatide achieved 47% higher weight reduction over 72 weeks than Novo Nordisk’s semaglutide…
-
Eli Lilly: New head-to-head trial data provides better conditions for doctors
Eli Lilly’s elderly clinical supervisor for Nordic nations assumes that the brand-new neck and neck research makes it simpler for physicians to suggest either Lilly’s o…
-
Coloplast divests products from core skin care business
Income from the unloaded items in the skin treatment service totaled up to around DKK 400m (USD 56.52 m) in fiscal year 2023/24.
-
Manhunt underway after shooting death of Manhattan CEO
The suspicious got here 5 mins prior to the supervisor and, according to cops, performed a targeted strike shooting 2 gunfires.
-
Analysts on new Eli Lilly obesity data: Confirms consensus on Zepbound and Wegovy
Wednesday’s neck and neck research study revealed a weight reduction of 20.2% for Eli Lilly’s Zepbound and 13.7% for Novo Nordisk’s Wegovy.
-
Analyst unsurprised by new obesity data from Eli Lilly
” The research verifies the previous presumption that Zepbound gives higher weight management than Wegovy,” states Sydbank expert Søren Løntoft Hansen.
-
Genmab secures rights to second Scancell antibody in new million-dollar deal
An arrangement in between Genmab and UK-based Scancell consists of an in advance repayment and prospective growth, governing and industrial landmark settlements of as much as USD 6…
-
Eli Lilly study concludes: Tirzepatide is better for weight loss than Novo Nordisk’s semaglutide
Generally, tirzepatide created a 47% better family member weight management contrasted to semaglutide, according to Eli Lilly.
-
Danish biotech company raises serious capital to develop new obesity drug
With brand-new financier assistance, Antag Rehabs can send out a brand-new weight problems prospect right into the scientific stage. According to the business’s chief executi…